Electra Therapeutics IPO: $15 pricing on 2026-09-17
Electra Therapeutics priced 23,333,334 shares at $15 in its dated 2026-09-17 announcement, with approximately $350.0 million base gross proceeds.
Dated offering terms — 2026-09-17
Electra Therapeutics announced a price of $15 for 23,333,334 shares, representing about $350.0 million before fees. Its announcement expected Nasdaq Global Select Market trading under ETRA on 18 September 2026.
Electra describes itself as a late clinical-stage developer of precision medicines for immune-mediated diseases and cancer. The upsized offering included an underwriter option for 3,500,000 additional shares, separate from the base transaction.
What the financing changes
A larger financing increases resources, while also increasing the number of claims on future business value. That makes the relationship between funding and achievable development milestones central. Readers should look for evidence about trial progress, recruitment and the cost of the next major studies. Portfolio breadth can spread scientific opportunities but can also spread capital across competing priorities. The financing announcement provides the starting capital-market terms; it does not resolve those operating trade-offs.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.